These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Is there a role for colchicine in secondary prevention of coronary artery disease? Sudevan R Eur J Prev Cardiol; 2022 Feb; 28(17):1914-1915. PubMed ID: 34219144 [No Abstract] [Full Text] [Related]
4. Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underling possible safety concerns. Galli M; Princi G; Crea F; D'Amario D Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):e18-e19. PubMed ID: 33270128 [No Abstract] [Full Text] [Related]
6. Response-letter to the editor: colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. Galli M; Princi G; Crea F; D'Amario D Eur Heart J Cardiovasc Pharmacother; 2021 Jul; 7(4):e72-e73. PubMed ID: 33725116 [No Abstract] [Full Text] [Related]
7. [Colchicine in patients with coronary heart disease : LoDoCo2 trial]. Koenig W; Nitschmann S Internist (Berl); 2021 Mar; 62(3):333-336. PubMed ID: 33580309 [No Abstract] [Full Text] [Related]
8. Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. Fiolet ATL; Opstal TSJ; Mosterd A; Eikelboom JW; Nidorf SM; Thompson PL; Budgeon C; Tijssen JGP; Cornel JH Eur Heart J Cardiovasc Pharmacother; 2021 Jul; 7(4):e71. PubMed ID: 33713121 [No Abstract] [Full Text] [Related]
9. COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Akodad M; Lattuca B; Nagot N; Georgescu V; Buisson M; Cristol JP; Leclercq F; Macia JC; Gervasoni R; Cung TT; Cade S; Cransac F; Labour J; Dupuy AM; Roubille F Arch Cardiovasc Dis; 2017; 110(6-7):395-402. PubMed ID: 28065445 [TBL] [Abstract][Full Text] [Related]
10. Comment on "Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials". Liang H; Huang D Br J Clin Pharmacol; 2022 Jun; 88(6):3000-3001. PubMed ID: 35118689 [No Abstract] [Full Text] [Related]
11. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Fiolet ATL; Opstal TSJ; Mosterd A; Eikelboom JW; Jolly SS; Keech AC; Kelly P; Tong DC; Layland J; Nidorf SM; Thompson PL; Budgeon C; Tijssen JGP; Cornel JH Eur Heart J; 2021 Jul; 42(28):2765-2775. PubMed ID: 33769515 [TBL] [Abstract][Full Text] [Related]
12. In patients with CAD, adding colchicine to evidence-based therapies reduces MACE without increasing adverse outcomes. Bates ER Ann Intern Med; 2021 Mar; 174(3):JC30. PubMed ID: 33646848 [TBL] [Abstract][Full Text] [Related]
13. Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease. Xia M; Yang X; Qian C Am J Cardiol; 2021 Feb; 140():33-38. PubMed ID: 33137319 [TBL] [Abstract][Full Text] [Related]
14. Lessons from COLCOT and LoDoCo2: colchicine for secondary prevention in coronary artery disease. Bouabdallaoui N; Blondeau L; Tardif JC Eur Heart J; 2021 Jul; 42(28):2800-2801. PubMed ID: 33496313 [No Abstract] [Full Text] [Related]
15. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Nidorf SM; Thompson PL Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286 [TBL] [Abstract][Full Text] [Related]
16. Colchicine for acute and chronic coronary syndromes. Imazio M; Andreis A; Brucato A; Adler Y; De Ferrari GM Heart; 2020 Oct; 106(20):1555-1560. PubMed ID: 32611559 [TBL] [Abstract][Full Text] [Related]